

8 weeks = 56 days
 3 months = 84 days
 6 months = 168 days

COVID-19 Vaccine Quick Reference

Table-1: Recommended Schedule (excluding severely or moderately immunocompromised)

Ages 6 mths through 4 years	Vaccine	Primary Series	Boosters
5 th birthday and onward to receive Pfizer pediatric ***Children must complete series with the same product. Children who started with Moderna and turn 5 years prior to completing their primary series are recommended to complete with Moderna.	Moderna infant formulation (royal blue cap)	2 dose series 8 weeks apart (minimum 28 days with informed consent) Dosage: 0.25 ml (25 mcg)	No
	Pfizer infant formulation (maroon cap)	3 dose series 2nd dose, 8 weeks after 1 st dose (minimum 21 days with informed consent) 3rd dose, 8 weeks after 2 nd dose (no other minimum interval) Dosage: 0.2 ml (3 mcg)	No
Ages 5 to 11	Vaccine	Primary Series	Boosters
Must be 5 yrs on day of vaccination *Preferentially to receive Pfizer over Moderna *Pfizer pediatric Bivalent recommended for booster doses, but can receive monovalent Pfizer if requested	Pfizer pediatric formulation (orange cap)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.2 ml (10 mcg)	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.2 ml (10 mcg)
	Pfizer pediatric formulation Bivalent (orange cap)	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.2 ml (10 mcg)
Ages 12 to 17	Vaccine	Primary Series	Boosters
*Preferentially to receive Pfizer over Moderna *Pfizer Bivalent recommended for booster doses, but can receive monovalent Pfizer if requested	Pfizer Adult/Adolescent formulation (grey cap)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.3 ml (30 mcg)	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
	Pfizer Bivalent (dark gray cap)	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
Ages 18 +	Vaccine	Primary Series	Boosters
<ul style="list-style-type: none"> • 18 to 29 receive Pfizer for primary series (Moderna if requested with informed consent) • 30+ can receive Pfizer or Moderna for primary series • Bivalent vaccines are recommended for boosters. People should only get monovalent if requested • Evidence shows both bivalent vaccines induce a stronger & more robust immune response, & are expected to provide ↑ protection against the Omicron variant and subvariants compared to 	Pfizer Adult/Adolescent formulation (grey cap)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.3 ml (30 mcg)	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
	Moderna Monovalent (red cap for 100mcg blue or red for 50 mcg)	2 dose series 8 weeks apart (minimum 28 days with informed consent) Dosage: 0.5 ml (100 mcg)	6 months after last dose (minimum 3 months with informed consent) Dosage: Under 70 = 0.25ml (50 mcg) 70+ & congregate = 0.5 ml (100 mcg)
	Moderna Bivalent (blue cap/green label)	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Recommended 3 months for high risk Dosage: 0.5ml (50 mcg)

original mRNA vaccines. And help restore immunity that has decreased since previous vaccination.			
	Pfizer Bivalent (dark gray cap)	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Recommended 3 months for high risk Dosage: 0.3 ml (30 mcg)
	Novavax (For those who can't/won't receive mRNA vaccines)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.5ml	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5ml

Table 2: Those who are Severely or Moderately Immunocompromised which includes:

- Receiving dialysis (hemodialysis or peritoneal dialysis)
- Receiving active treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Individuals with HIV with prior AIDS defining illness or prior CD4 count $\leq 200/\text{mm}^3$ or prior CD4 fraction $\leq 15\%$ or (in children 5-11 years) perinatally acquired HIV infection
- Individuals receiving active treatment with the specific immunosuppressive therapies (refer to list in directive)

	Vaccine	Primary Series	Boosters
Ages 6 mths through 4 yrs 5 th birthday and onward to receive Pfizer pediatric The preferential recommendation for monovalent Moderna (25 mcg) for this age group is due to feasibility of series completion rather than any safety signals observed.	Moderna Pediatric formulation (royal blue cap)	3 dose series 56 days between doses (minimum 28 days with informed consent) Dosage: 0.25 ml (25 mcg)	No
	Pfizer pediatric formulation (maroon cap)	4 dose series 2nd dose, 21 days after 1st dose 3rd dose, 56 days after 2nd dose 4th dose, 56 days after 3rd dose (no other minimum interval) Dosage: 0.2 ml (3 mcg)	No

Ages 5 to 11 *Preferentially to receive Pfizer over Moderna *Pfizer pediatric Bivalent recommended for booster doses, but can receive monovalent Pfizer if requested	Pfizer pediatric formulation (orange cap)	3 dose series 8 week between doses (minimum 28 days with informed consent) Dosage: 0.2 ml (10 mcg)	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.2 ml (10 mcg)
	Pfizer pediatric formulation Bivalent (orange cap)	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.2 ml (10 mcg)

Ages 12 to 17 *Preferentially to receive Pfizer over Moderna *Pfizer Bivalent recommended for booster doses, but can receive monovalent Pfizer if requested	Pfizer Adult/Adolescent formulation (grey cap)	3 dose series 8 weeks between doses (minimum 28 days with informed consent) Dosage: 0.3 ml (30 mcg)	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
	Pfizer Bivalent (dark grey cap)	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3ml (30 mcg)

<p>Ages 18 +</p> <ul style="list-style-type: none"> 18 to 29 to receive Pfizer for primary series (Moderna if requested with informed consent) 18+ recommended Bivalent for boosters. Only receive monovalent if requested 	Pfizer Adult/Adolescent formulation (grey cap)	<p>3 dose series</p> <p>8 weeks between doses (minimum 28 days with informed consent)</p> <p>Dosage: 0.3 ml (30 mcg)</p>	<p>6 months after last dose (minimum 3 months with informed consent)</p> <p>Dosage: 0.3 ml (30 mcg)</p>
	Moderna Monovalent (red cap)	<p>3 dose series</p> <p>8 weeks between doses (minimum 28 days with informed consent)</p> <p>Dosage: 0.5 ml (100 mcg)</p>	<p>6 months after last dose (minimum 3 months with informed consent)</p> <p>Dosage: 0.5 ml (100 mcg)</p>
	Moderna Bivalent	<p>N/A</p> <p>See above for primary series recommendations</p>	<p>6 months after last dose (minimum 3 months with informed consent)</p> <p>Dosage: 0.5ml (50 mcg)</p>
	Pfizer Bivalent (dark grey cap)	<p>N/A</p> <p>See above for primary series recommendations</p>	<p>6 months after last dose (minimum 3 months with informed consent)</p> <p>Dosage: 0.3ml (30 mcg)</p>
	Novavax	<p>3 dose series</p> <p>8 weeks between doses (minimum 21 days with informed consent)</p> <p>Dosage: 0.5 ml</p>	<p>6 months after last dose (minimum 3 months with informed consent)</p> <p>Dosage: 0.5 ml</p>

Severely or Moderately Immunocompromised: Re-immunization Recommendation

Those who have received a hematopoietic stem cell transplants (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy should be re-vaccinated with a new COVID-19 vaccine primary series post-transplantation due to the loss of immunity following therapy or transplant. For additional information, please refer to the updated [COVID-19 Vaccination Recommendations for Special Populations](#) document.

Post Infection Immunization Guidance

Infection timing relative to COVID-19 vaccination	Population	Suggested interval between infection* and vaccination
Infection prior to completion or initiation of primary vaccination series	Individuals 6 months of age and older who are not considered moderately to severely immunocompromised and with no previous history of multisystem inflammatory syndrome in children (MIS-C)	Receive the vaccine 2 months (56 days) after symptom onset or positive test (if asymptomatic)
	Individuals 6 months of age and older who are moderately to severely immunocompromised and with no previous history of MIS-C	Receive the vaccine dose 1 to 2 months (28 to 56 days) after symptom onset or positive test (if asymptomatic)
	Individuals 6 months of age and older with a previous history of MIS-C (regardless of immunocompromised status)	Receive the vaccine dose when clinical recovery has been achieved or ≥90 days since the onset of MIS-C, whichever is longer

Infection after primary series	Individuals currently eligible for booster dose(s)	A minimum of 3 months (84 days) after symptom onset or positive test (if asymptomatic); however, a 6 month (168 day) interval may provide better immune response regardless of the product given.

*A previous infection with SARS-CoV-2 is defined as:

- Confirmed by a molecular (e.g., PCR) or rapid antigen test; or
- Symptomatic **AND** a household contact of a confirmed COVID-19 case.